Key result
Cyclosporine and ART-18 prolong cardiac allograft survival in sensitized rats up to ~42 days.
Why the study?
The mechanisms by which anti-interleukin 2 receptor monoclonal antibody and cyclosporine modulate accelerated rejection of cardiac allografts in sensitized hosts were unclear.
Does ART-18 and/or cyclosporine therapy prolong cardiac allograft survival in sensitized rats?
Population
LEW rats sensitized with BN skin transplants receiving LBNF1 cardiac allografts
Comparison
Cyclosporine vs ART-18 vs combination of ART-18 and subtherapeutic cyclosporine vs untreated sensitized hosts
Design
Preclinical experimental study
Authors
Loading...
Hypothesis-generating for ART-18 in sensitized models; leaves open translation of adjunctive cyclosporine to clinical cardiac transplantation.
Does ART-18 and/or cyclosporine therapy prolong cardiac allograft survival in sensitized rats?
Adjunctive low-dose cyclosporine potentiates the inhibitory effects of ART-18 on humoral and cellular responses, prolonging cardiac allograft survival in presensitized rats.
Kupiec‐Weglinski et al. (1991) studied Accelerated rejection of cardiac allografts. ART-18 (anti-IL-2R mAb) and cyclosporine vs. untreated sensitized hosts was evaluated on Mean cardiac allograft survival. Treatment with cyclosporine or ART-18 prolonged mean cardiac allograft survival in sensitized rats to 42 days and 16 days, respectively, and combined therapy extended survival to 25 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: